TY  - GEN
AU  - Wang,Zhijie
AU  - Cheng,Ying
AU  - An,Tongtong
AU  - Gao,Hongjun
AU  - Wang,Kai
AU  - Zhou,Qing
AU  - Hu,Yanping
AU  - Song,Yong
AU  - Ding,Cuimin
AU  - Peng,Feng
AU  - Liang,Li
AU  - Hu,Yi
AU  - Huang,Cheng
AU  - Zhou,Caicun
AU  - Shi,Yuankai
AU  - Zhang,Li
AU  - Ye,Xin
AU  - Zhang,Meizhuo
AU  - Chuai,Shaokun
AU  - Zhu,Guanshan
AU  - Hu,Jin
AU  - Wu,Yi-Long
AU  - Wang,Jie
TI  - Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
SN  - 2213-2619
PY  - 2019///0531
KW  - Adenocarcinoma
KW  - drug therapy
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Biomarkers, Tumor
KW  - blood
KW  - Circulating Tumor DNA
KW  - DNA Mutational Analysis
KW  - methods
KW  - Disease-Free Survival
KW  - Female
KW  - Gefitinib
KW  - administration & dosage
KW  - Genes, Tumor Suppressor
KW  - Genes, erbB-1
KW  - Humans
KW  - Intention to Treat Analysis
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Protein Kinase Inhibitors
KW  - Sensitivity and Specificity
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S2213-2600(18)30264-9
ER  -